Skip to main navigation
Go to Nurix Therapeutics, Inc.  homepage
Nurix Therapeutics, Inc.
  • Inside The Science
    • DEL-AI Discovery Engine
    • Targeted Protein Degradation
    • Resource Library
  • Advancing Our Pipeline
    • Pipeline
    • Clinical Trials
  • Learn About Us
    • Our Story
    • Leadership
    • Partnering
    • Contact Us
  • Work at Nurix
    • Our Culture
    • Explore Jobs
Patients
Patients
Investors & News
Investors & News
Go to Nurix Therapeutics, Inc.  homepage
Nurix Therapeutics, Inc.
  • Inside The Science
    • DEL-AI Discovery Engine
    • Targeted Protein Degradation
    • Resource Library
  • Advancing Our Pipeline
    • Pipeline
    • Clinical Trials
  • Learn About Us
    • Our Story
    • Leadership
    • Partnering
    • Contact Us
  • Work at Nurix
    • Our Culture
    • Explore Jobs

FOR INVESTORS

Press releases

  • Overview
  • Press Releases
  • Events
  • Financial Info
  • Stock
  • Governance
  • FAQs
November 11, 2026
Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer
November 10, 2026
Nurix Therapeutics to Participate in Upcoming Investor Conferences
November 5, 2026
Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition
November 3, 2026
Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272
October 12, 2026
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
October 7, 2026
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
October 5, 2026
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
September 29, 2026
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
September 1, 2026
Nurix Therapeutics to Participate in Upcoming September Investor Conferences
August 20, 2026
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
  • Current page 1
  • Page 2
  • Page 3
  • Next page Next ›
  • Last page Last ›
Displaying 1 - 10 of 26
Print Page (opens in new tab)

Print Page

Contact IR (opens in new tab)

Contact IR

RSS (opens in new tab)

RSS

Email Alerts (opens in new tab)

Email Alerts

Go to Nurix Therapeutics, Inc.  homepage

WHERE SCIENCE EXPANDS POSSIBILITIES

Inside The Science

  • DEL-AI Discovery Engine
  • Targeted Protein Degradation
  • Resource Library

Advancing Our Pipeline

  • Pipeline
  • Clinical Trials

Learn About Us

  • Our Story
  • Leadership
  • Partnering
  • Contact Us

Work at Nurix

  • Our Culture
  • Explore Jobs

For Investors

  • News
  • Financial Information
  • Stock Information
  • Corporate Governance
  • FAQs
  • Investor Contact

For Patients

  • Resources

©2026 Nurix Therapeutics, Inc.

Privacy Policy

Terms of Use

Cookie Policy

Privacy Policy

Terms of Use

Cookie Policy